Petros Pharmaceuticals Assigns All Assets to Liquidation Trust; Executives Resign

What happened

Petros Pharmaceuticals, Inc. (ticker PTPI) entered into a General Assignment for the Benefit of Creditors on September 30, 2026, according to a Form 8-K the company filed that day. Under the agreement, made under California law, the company assigned all of its right, title, and interest in its assets to PT Liquidation, LLC, acting as Assignee, for the benefit of the company's creditors.

The filing states the assignment constitutes a liquidation event. The Assignee will take possession of the company's assets and administer them under applicable state law to satisfy creditor claims to the extent possible. As a result, Petros says it has ceased substantially all business operations and no longer has the ability to continue as a going concern.

The same filing reports that the assignment triggered defaults or acceleration rights under some of the company's contractual obligations and a triggering event under the Certificate of Designations for its Series A Convertible Preferred Stock. Under that certificate, all outstanding obligations under those agreements may become immediately due and payable, and the company is required to immediately redeem all outstanding shares of the Series A Convertible Preferred Stock.

Three board members resigned effective September 30, 2026: Executive Chairman Joshua N. Silverman, Bruce T. Bernstein, and Wayne R. Walker. Fady Boctor was terminated as President and Chief Commercial Officer that day, and Robert Weinstein resigned as Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer effective 5:30 p.m. Eastern time. The filing states these departures were not the result of any disagreement with the company on any matter relating to its operations, policies, or practices.

What the company does

Petros Pharmaceuticals is a pharmaceutical preparations company incorporated in Delaware with principal offices at 1185 Avenue of the Americas, New York. The Form 8-K lists no securities registered under Section 12(b) of the Exchange Act, and states the company is an emerging growth company as defined under SEC rules. It trades under the ticker PTPI.

Market reaction

The stock closed at $0.007 on the event date, up 40% from the prior close of $0.005, according to the price data. The move came on a share price already below one cent.

What this means

A General Assignment for the Benefit of Creditors is an alternative to a formal bankruptcy filing. Rather than petitioning a court under Chapter 7 or Chapter 11, a company transfers legal title to its assets to a third-party assignee, who liquidates them and distributes the proceeds to creditors under state law. Here the assets went to PT Liquidation, LLC, and the governing law is California's. The 8-K reports the contact address for further information as PT Liquidation, LLC, 2261 Market Street, Suite 95526, San Francisco.

A Form 8-K is the current report public companies file to disclose material events between quarterly and annual reports. The items listed determine what must be disclosed. Item 1.03 covers bankruptcy or receivership. Item 2.04 covers triggering events that accelerate or increase a direct financial obligation or an off-balance-sheet obligation. Item 5.02 covers the departure or election of directors and certain officers. This filing uses all three.

The Series A Convertible Preferred Stock mentioned in Item 2.04 is a class of equity that ranks ahead of common stock and can be converted into common shares. The Certificate of Designations is the document that sets its terms, including what counts as a triggering event and what the company must do when one occurs. According to the filing, the assignment itself triggered a requirement to immediately redeem all outstanding shares of that series. In a liquidation, preferred holders generally have claims ahead of common shareholders, and the filing says the company may also face obligations becoming immediately due under other contracts.

The assignment is a process run by the Assignee, not by the company. The filing's forward-looking statements note that actual results may differ from expectations due to factors including the Assignee's ability to administer the assets and claims effectively. Distributions to creditors depend on how much the assets realize and how claims are resolved, and the filing does not state a timetable or an estimated recovery for any class of creditor or shareholder.